NASDAQ:ILMN - Illumina Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$286.76 +1.02 (+0.36 %)
(As of 06/20/2018 01:24 PM ET)
Previous Close$287.83
Today's Range$285.25 - $288.73
52-Week Range$167.98 - $293.15
Volume27,148 shs
Average Volume650,754 shs
Market Capitalization$42.46 billion
P/E Ratio71.70
Dividend YieldN/A
Beta0.88
Illumina logoIllumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array. The company also provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and noninvasive prenatal testing, as well as products support services. It serves genomic research centers, academic institutions, government laboratories, and hospitals; and pharmaceutical, biotechnology, agrigenomics, and commercial molecular diagnostic laboratories, as well as consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. It operates in North America, Europe, Latin America, the Asia-Pacific region, the Middle East, and South Africa. The company has a strategic partnership with Loxo Oncology, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and strategic collaboration with Bristol-Myers Squibb Company. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.

Receive ILMN News and Ratings via Email

Sign-up to receive the latest news and ratings for ILMN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNASDAQ:ILMN
CUSIP45232710
Phone858-202-4500

Debt

Debt-to-Equity Ratio0.23
Current Ratio2.71
Quick Ratio2.41

Price-To-Earnings

Trailing P/E Ratio71.70
Forward P/E Ratio59.00
P/E Growth3.09

Sales & Book Value

Annual Sales$2.75 billion
Price / Sales15.32
Cash Flow$5.2830 per share
Price / Cash54.28
Book Value$18.83 per share
Price / Book15.23

Profitability

EPS (Most Recent Fiscal Year)$4.00
Net Income$726 million
Net Margins19.31%
Return on Equity24.93%
Return on Assets13.72%

Miscellaneous

Employees6,200
Outstanding Shares147,000,000

Illumina (NASDAQ:ILMN) Frequently Asked Questions

What is Illumina's stock symbol?

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) announced its quarterly earnings data on Tuesday, April, 24th. The life sciences company reported $1.45 EPS for the quarter, topping the Zacks' consensus estimate of $1.02 by $0.43. The life sciences company earned $782 million during the quarter, compared to the consensus estimate of $744.30 million. Illumina had a return on equity of 24.93% and a net margin of 19.31%. The company's quarterly revenue was up 30.8% on a year-over-year basis. During the same quarter last year, the company earned $0.64 EPS. View Illumina's Earnings History.

When is Illumina's next earnings date?

Illumina is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Illumina.

What guidance has Illumina issued on next quarter's earnings?

Illumina updated its FY18 earnings guidance on Tuesday, April, 24th. The company provided earnings per share (EPS) guidance of $4.75-4.85 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.59. The company issued revenue guidance of +15-16% to ~$3.16-3.19 billion, compared to the consensus revenue estimate of $3.14 billion.

What price target have analysts set for ILMN?

19 brokerages have issued 12 month price objectives for Illumina's stock. Their forecasts range from $195.00 to $290.00. On average, they expect Illumina's share price to reach $254.5625 in the next twelve months. View Analyst Ratings for Illumina.

What are Wall Street analysts saying about Illumina stock?

Here are some recent quotes from research analysts about Illumina stock:
  • 1. According to Zacks Investment Research, "In the last three months, Illumina outperformed its industry. The company’s recent strategic collaborations are expected to expand its product portfolio. This apart an improving margin scenario should also instill confidence on the stock. Currently, Illumina is focusing on product innovation through research and development as well, which is evident from the launch of iSeq 100 Sequencing System recently. Post a promising fourth-quarter show, we expect Illumina to maintain its growth momentum on continued uptake of sequencing consumables, instruments and microarray portfolios. On the flip side, the company is operating in a tough competitive landscape which is a concern. Further, the stock looks a bit overvalued at the moment." (4/16/2018)
  • 2. Canaccord Genuity analysts commented, "Shipments to China grew +16% and we believe China is likely to be a double-digit grower for ILMN over the next several years, driven by the Chinese Precision Medicine Initiative," (8/7/2017)

Who are some of Illumina's key competitors?

Who are Illumina's key executives?

Illumina's management team includes the folowing people:
  • Mr. Jay T. Flatley, Exec. Chairman (Age 65)
  • Mr. Francis A. deSouza, CEO, Pres & Director (Age 47)
  • Mr. Sam A. Samad, CFO & Sr. VP (Age 48)
  • Mr. Omead Ostadan, Exec. VP of Operations and Products (Age 46)
  • Mr. Marc A. Stapley, Exec. VP of Strategy & Corp. Devel. (Age 48)

Has Illumina been receiving favorable news coverage?

Media coverage about ILMN stock has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Illumina earned a news sentiment score of 0.11 on Accern's scale. They also assigned press coverage about the life sciences company an impact score of 46.47 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are Illumina's major shareholders?

Illumina's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (12.02%), Edgewood Management LLC (3.51%), Winslow Capital Management LLC (0.64%), Prudential Financial Inc. (0.52%), American Century Companies Inc. (0.52%) and Legal & General Group Plc (0.45%). Company insiders that own Illumina stock include A Blaine Bowman, Charles Dadswell, Christian O Henry, Daniel Bradbury, Frances Arnold, Francis A Desouza, Jay T Flatley, Karin Eastham, Marc Stapley, Michel Bouchard, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Robert S Epstein and Roy A Whitfield. View Institutional Ownership Trends for Illumina.

Which institutional investors are selling Illumina stock?

ILMN stock was sold by a variety of institutional investors in the last quarter, including Winslow Capital Management LLC, Baillie Gifford & Co., Sei Investments Co., Swiss National Bank, Reynders McVeigh Capital Management LLC, Van ECK Associates Corp, Guggenheim Capital LLC and New York State Common Retirement Fund. Company insiders that have sold Illumina company stock in the last year include A Blaine Bowman, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karin Eastham, Marc Stapley, Michel Bouchard, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan and Robert S Epstein. View Insider Buying and Selling for Illumina.

Which institutional investors are buying Illumina stock?

ILMN stock was purchased by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Prudential Financial Inc., Rockefeller Capital Management L.P., Summit Trail Advisors LLC, Millennium Management LLC, Lord Abbett & CO. LLC, American Century Companies Inc. and Scout Investments Inc.. View Insider Buying and Selling for Illumina.

How do I buy shares of Illumina?

Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Illumina's stock price today?

One share of ILMN stock can currently be purchased for approximately $286.94.

How big of a company is Illumina?

Illumina has a market capitalization of $42.46 billion and generates $2.75 billion in revenue each year. The life sciences company earns $726 million in net income (profit) each year or $4.00 on an earnings per share basis. Illumina employs 6,200 workers across the globe.

How can I contact Illumina?

Illumina's mailing address is 5200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at 858-202-4500 or via email at [email protected]


MarketBeat Community Rating for Illumina (ILMN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  749 (Vote Outperform)
Underperform Votes:  736 (Vote Underperform)
Total Votes:  1,485
MarketBeat's community ratings are surveys of what our community members think about Illumina and other stocks. Vote "Outperform" if you believe ILMN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ILMN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.